Design and Antischizophrenic Studies of 1,3-disubstituted Chalcone Derivatives: In-silico Molecular Docking Approach
Main Article Content
Abstract
Schizophrenia is a psychiatric disorder that affects a person’s ability to think, feel and behave clearly. The pathophysiology of the disease stems from the overexpression of dopamine neurotransmission and deficiency of glutamate activity at glutamate synapse in the brain. Considering the significant global burden of the disease, lack of complete efficacy using the current medications and variety of adverse effects associated with their use, and the huge opportunity created by Computer-Aided Drug Design, it is therefore important and possible to come up with drug leads that will have improved efficacy and reduced side effects. This research is thus aimed to design, evaluate the pharmacokinetic properties, and the in silico antischizophrenic activity of novel 1,3-disubstituted chalcones. Ten compounds were designed using ChemDraw Ultra 7.0 using similarity approach and their oral bioavailability was predicted using SwissADME, toxicity was predicted using PROTOX 3.0 and docking studies were carried out using AutoDock Vina through Chimera 1.11.2. The 10 designed compounds were predicted to have excellent oral bioavailability and lead-likeness properties, easy synthesisability and a relatively safer toxicity profile than the reference compound clozapine. The compounds were evaluated to have higher docking scores between –8.3 to –9.5 compared to clozapine with a docking score of -8.8 when docked against dopaminergic D2 receptor. In addition, the compounds have close binding scores (–6.0 to –6.6) compared to clozapine (–6.7) when docked against N-Methyl-D-aspartic Acid (NMDA) receptor, suggesting their use as potential antischizophrenic agents.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Abdullahi M and Adeniji S E. (2020). In-silico molecular docking and ADME/Pharmacokinetic prediction studies of some novel carboxamide derivatives as anti-tubercular agents. Chemistry Africa 3(4): 989–1000. https://doi.org/10.1007/s42250-020-00162-3
Blair D and Dauner A. (1992). Extrapyramidal symptoms are serious side-effects of antipsychotic and other drugs. The Nurse Practitioner 17(11): 56, 62, 63, 64, 67. https://doi.org/10.1097/00006205-199211000-00018
Carbon M and Correll C U. (2014). Thinking and acting beyond the positive: The role of the cognitive and negative symptoms in schizophrenia. CNS Spectrums 19(S1): 35–53. https://doi.org/10.1017/s1092852914000601
Chintha V and Wudayagiri R. (2019). Bioavailability and neuroprotectivity of 3-(3, 4-dimethoxy phenyl)-1-4 (methoxy phenyl) prop-2-en-1-one against Schizophrenia: An in silico approach. Journal of Receptors and Signal Transduction 39(5–6): 392–398. https://doi.org/10.1080/10799893.2019.1702689
Diana A, Michielin O and Zoete V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, druglikeness and medicinal chemistry friendliness of small molecules. Scientific Reports 7: 42717. https://doi.org/10.1038/srep42717
Drwal M N, Banerjee P, Dunkel M, Wettig M R and Preißner R. (2014). ProTox: A web server for the in silico prediction of rodent oral toxicity. Nucleic Acids Research 42(W1): W53–W58. https://doi.org/10.1093/nar/gku401
Fu Y, Zhao J and Chen Z. (2018). Insights into the molecular mechanisms of protein-ligand interactions by molecular docking and molecular dynamics simulation: A case of oligopeptide binding protein. Computational and Mathematical Methods in Medicine 2018: 1–12. https://doi.org/10.1155/2018/3502514
Hitchcock S A and Pennington L D. (2006). Structure−brain exposure relationships. Journal of Medicinal Chemistry 49(26): 7559–7583. https://doi.org/10.1021/jm060642i
Klein C, Kaiser D, Kopp S, Chiba P and Ecker G F. (2002). Similarity based SAR (SIBAR) as tool for early ADME profiling. Journal of Computer-Aided Molecular Design 16(11): 785–793. https://doi.org/10.1023/a:1023828527638
Lanman B A, Allen J R, Allen J G, Amegadzie A K, Ashton K S, Booker S K, Chen J J, et al. (2020). Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. Journal of Medicinal Chemistry 63(1): 52–65. https://doi.org/10.1021/acs.jmedchem.9b01180
Leucht S, Cipriani A, Spineli L M, Mavridis D, Örey D, Richter F, Samara M, et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. The Lancet 382(9896): 951–962. https://doi.org/10.1016/s0140-6736(13)60733-3
Li P, Snyder G L and Vanover K E. (2016). Dopamine targeting drugs for the treatment of schizophrenia: Past, present and future. Current Topics in Medicinal Chemistry 16(29): 3385–3403. https://doi.org/10.2174/1568026616666160608084834.
Lipinski C A, Lombardo F, Dominy B W and Feeney P J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 46(1–3): 3–26. https://doi.org/10.1016/s0169-409x(00)00129-0
Mellini M, Di Muzio E, D’Angelo F, Baldelli V, Ferrillo S, Visca P, Leoni L, Polticelli F and Rampioni G. (2019). In silico selection and experimental validation of FDA-approved drugs as anti-quorum sensing agents. Frontiers in Microbiology 10: 2355. https://doi.org/10.3389/fmicb.2019.02355
Menchaca T M, Juárez-Portilla C and Zepeda R. (2020). Past, present, and future of molecular docking. In V Galtonde, P Karmakar and A Trivedi (eds.), Drug discovery and development: New advances. IntechOpen. https://doi.org/10.5772/intechopen.90921
Miyamoto S, Duncan G E, Marx C E and Lieberman J A. (2004). Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 10(1): 79–104. https://doi.org/10.1038/sj.mp.4001556
Niazi S K and Mariam Z. (2023). Computer-aided drug design and drug discovery: A prospective analysis. Pharmaceuticals 17(1): 22. https://doi.org/10.3390/ph17010022
Ouma R B O, Ngari S M and Kibet J K. (2024). A review of the current trends in computational approaches in drug design and metabolism. Discover Public Health 21: 108. https://doi.org/10.1186/s12982-024-00229-3
Pajouhesh H and Lenz G R. (2005). Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2(4): 541–553. https://doi.org/10.1602/neurorx.2.4.541
Paul S M, Yohn S E, Popiolek M, Miller A and Felder C C. (2022). Muscarinic acetylcholine receptor agonists as new treatments for schizophrenia. American Journal of Psychiatry 179(9): 611–627. https://doi.org/10.1176/appi.ajp.21101083
Pettersen E F, Goddard T D, Huang C C, Couch G S, Greenblatt D M, Meng E C and Ferrin T E. (2004). UCSF Chimera: A visualization system for exploratory research and analysis. Journal of Computational Chemistry 25(13): 1605–1612. https://doi.org/10.1002/jcc.20084
Sabe V T, Ntombela T, Jhamba L A, Maguire G E, Govender T, Naicker T and Kruger H G. (2021). Current trends in computer-aided drug design and a highlight of drugs discovered via computational techniques: A review. European Journal of Medicinal Chemistry 224: 113705. https://doi.org/10.1016/j.ejmech.2021.113705
Stahl S M. (2018). Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: Dopamine, serotonin, and glutamate. CNS Spectrums 23(3): 187–191. https://doi.org/10.1017/s1092852918001013
Stępnicki P, Kondej M and Kaczor A A. (2018). Current concepts and treatments of schizophrenia. Molecules 23(8): 2087. https://doi.org/10.3390/molecules23082087
Stone J, Pepper F, Fam J, Furby H, Hughes E, Morgan P G and Howes O. (2013). Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users. Psychopharmacology 231(10): 2107–2116. https://doi.org/10.1007/s00213-013-3354-8
Snyder S H, Banerjee S, Yamamura H I and Greenberg D A. (1974). Drugs, neurotransmitters, and schizophrenia. Science 184(4143): 1243–1253. https://doi.org/10.1126/science.184.4143.1243
Tuttle J B., Allais C, Allerton C M N, Anderson A S, Arcari J T, Aschenbrenner L M, Avery M, et al. (2025). Discovery of Nirmatrelvir (PF-07321332): A potent, orally active inhibitor of the severe acute respiratory syndrome Coronavirus 2 (SARS CoV-2) main protease. Journal of Medicinal Chemistry 68(7): 7003–7030. https://doi.org/10.1021/acs.jmedchem.4c02561
Ugbaja S C, Mushebenge A G, Kumalo H, Ngcobo M and Gqaleni N. (2025). Potential benefits of in silico methods: A promising alternative in natural compound’s drug discovery and repurposing for HBV therapy. Pharmaceuticals 18(3): 419. https://doi.org/10.3390/ph18030419
Venkataramaiah C. (2020). Modulations in the ATPases during ketamine-induced schizophrenia and regulatory effect of “3-(3, 4-dimethoxy phenyl) -1- (4-methoxyphenyl) prop-2-en-1-one”: An in vivo and in silico studies. Journal of Receptors and Signal Transduction 40(2): 148–156. https://doi.org/10.1080/10799893.2020.1720242
Venkataramaiah C, Payani S, Priya B L and Pradeepkiran J A. (2021). Therapeutic potentiality of a new flavonoid against ketamine induced glutamatergic dysregulation in schizophrenia: In vivo and in silico approach. Biomedicine & Pharmacotherapy 138: 111453. https://doi.org/10.1016/j.biopha.2021.111453
World Health Organization (WHO). (2022, January 10). Schizophrenia. https://www.who.int/news-room/fact-sheets/detail/schizophrenia (accessed on 29 May 2024).
Zhao Y H, Abraham M H, Le J, Hersey A, Luscombe C, Beck G, Sherborne B and Cooper I. (2002). Rate-limited steps of human oral absorption and QSAR studies. Pharmaceutical Research 19(10): 1446–1457. https://doi.org/10.1023/a:1020444330011
Zhuang C, Zhang W, Sheng C, Zhang W and Xing C. (2017). Chalcone: A privileged structure in medicinal chemistry. Chemical Reviews 117(12): 7762–7810. https://doi.org/10.1021/acs.chemrev.7b00020